CA2786550C - Removal of virulence factors through extracorporeal therapy - Google Patents

Removal of virulence factors through extracorporeal therapy Download PDF

Info

Publication number
CA2786550C
CA2786550C CA2786550A CA2786550A CA2786550C CA 2786550 C CA2786550 C CA 2786550C CA 2786550 A CA2786550 A CA 2786550A CA 2786550 A CA2786550 A CA 2786550A CA 2786550 C CA2786550 C CA 2786550C
Authority
CA
Canada
Prior art keywords
beads
toxin
blood
heparin
anthrax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2786550A
Other languages
English (en)
French (fr)
Other versions
CA2786550A1 (en
Inventor
Keith Mccrea
Robert S. Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exthera Medical Corp
Original Assignee
Exthera Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exthera Medical Corp filed Critical Exthera Medical Corp
Publication of CA2786550A1 publication Critical patent/CA2786550A1/en
Application granted granted Critical
Publication of CA2786550C publication Critical patent/CA2786550C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • External Artificial Organs (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2786550A 2010-02-09 2011-02-09 Removal of virulence factors through extracorporeal therapy Active CA2786550C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30282610P 2010-02-09 2010-02-09
US61/302,826 2010-02-09
PCT/US2011/024229 WO2011100354A1 (en) 2010-02-09 2011-02-09 Removal of virulence factors through extracorporeal therapy

Publications (2)

Publication Number Publication Date
CA2786550A1 CA2786550A1 (en) 2011-08-18
CA2786550C true CA2786550C (en) 2018-03-13

Family

ID=43975201

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2786550A Active CA2786550C (en) 2010-02-09 2011-02-09 Removal of virulence factors through extracorporeal therapy

Country Status (9)

Country Link
US (1) US20120305482A1 (enExample)
EP (1) EP2533828B1 (enExample)
JP (2) JP5774607B2 (enExample)
KR (1) KR101486879B1 (enExample)
CN (1) CN102791307B (enExample)
AU (1) AU2011215942B8 (enExample)
CA (1) CA2786550C (enExample)
ES (1) ES2728122T3 (enExample)
WO (1) WO2011100354A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069983A1 (en) 2005-12-13 2007-06-21 Exthera Ab Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
WO2008155683A1 (en) 2007-06-18 2008-12-24 Firmenich Sa Malodor counteracting compositions and method for their use
JP5925693B2 (ja) 2009-12-01 2016-05-25 エクステラ・メディカル・コーポレーション 表面固定した多糖類を用いた、血液からのサイトカイン除去法
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
ES2647577T3 (es) 2012-06-13 2017-12-22 Exthera Medical Corporation Uso de heparina y carbohidratos para tratar el cáncer
US20150335576A1 (en) 2012-06-29 2015-11-26 Cytosorbents Corporation Methods of using polymers
CN105339067A (zh) * 2013-06-24 2016-02-17 艾克塞拉医疗公司 含有涂覆甘露糖的基质的血液过滤系统
EP3065796B1 (en) * 2013-11-08 2020-04-15 ExThera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
JP2017513636A (ja) 2014-04-24 2017-06-01 エクスセラ メディカル コーポレイション 高流量を用いて血液から細菌を除去するための方法
CA2959975A1 (en) 2014-09-22 2016-03-31 Exthera Medical Corporation Wearable hemoperfusion device
WO2017151797A1 (en) 2016-03-02 2017-09-08 Exthera Medical Corporation Method for treating drug intoxication
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US10822461B2 (en) 2017-10-05 2020-11-03 Fresenius Medical Care Holdings, Inc. Polysulfone-urethane copolymer, membranes and products incorporating same, and methods for making and using same
EP3735281B1 (en) 2018-01-05 2024-11-27 Path Ex, Inc. Device for the capture and removal of disease material from fluids
CN113825517A (zh) * 2019-05-16 2021-12-21 艾克塞拉医疗公司 调节内皮糖萼结构的方法
JP2023550942A (ja) * 2020-11-30 2023-12-06 アルテコ メディカル アクティエボラーグ 体液から少なくとも１つの成分を結合及び分離するための装置
HUP2200216A1 (hu) 2022-06-15 2023-12-28 Captec Medical Kft Nagy teljesítményû, immun-affinitáson alapuló, extrakorporális patogén csapda

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916352A1 (de) * 1999-04-12 2000-10-19 Braun Melsungen Ag Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum
US6803183B2 (en) * 2002-07-18 2004-10-12 Clarigen, Inc. Method for removing pyrogens from plasma and blood for treatment of septic shock
EP1624785B1 (en) * 2003-01-17 2013-07-17 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
EP1793837A2 (en) * 2004-09-27 2007-06-13 Technion Research & Development Foundation Limited Fatty acid modified polylysines as antimicrobial agents
WO2007069983A1 (en) * 2005-12-13 2007-06-21 Exthera Ab Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
WO2008157570A2 (en) * 2007-06-18 2008-12-24 Exthera Ab Device and method for restoration of the condition of blood

Also Published As

Publication number Publication date
ES2728122T3 (es) 2019-10-22
US20120305482A1 (en) 2012-12-06
EP2533828A1 (en) 2012-12-19
AU2011215942A1 (en) 2012-07-26
CN102791307A (zh) 2012-11-21
KR20120123692A (ko) 2012-11-09
WO2011100354A1 (en) 2011-08-18
AU2011215942B2 (en) 2014-01-30
JP2013518687A (ja) 2013-05-23
JP5774607B2 (ja) 2015-09-09
AU2011215942B8 (en) 2014-02-13
EP2533828B1 (en) 2019-02-27
KR101486879B1 (ko) 2015-01-28
CN102791307B (zh) 2016-05-18
JP2015131831A (ja) 2015-07-23
CA2786550A1 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
AU2011215942B8 (en) Removal of virulence factors through extracorporeal therapy
US11123466B2 (en) Methods for removing cytokines from blood with surface immobilized polysaccharides
US10537280B2 (en) Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
US11266772B2 (en) Use of heparin and carbohydrates to treat cancer
CN106714669A (zh) 可穿戴的血液灌流装置
HK1176572A (en) Removal of virulence factors through extracorporeal therapy
HK1176572B (en) Removal of virulence factors through extracorporeal therapy
AU2014277852B2 (en) Method for removing cytokines from blood with surface immobilized polysaccharides
HK1177151B (en) Method for removing cytokines from blood with surface immobilized polysaccharides

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250129

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250129

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250129

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260110

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260110